Brief: ZyVersa Therapeutics Reports Q1 2023 Corporate And Financial Results
12/05/2023 14:10
May 12 (Reuters) - Zyversa Therapeutics Inc ZVSA.O :
* ZYVERSA THERAPEUTICS REPORTS FIRST QUARTER 2023 CORPORATE
AND
FINANCIAL RESULTS
* ZYVERSA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.39
* ZYVERSA THERAPEUTICS INC - CASH AS OF MARCH 31, TO BE
SUFFICIENT
TO FUND OPERATING EXPENSES & CAPEX REQUIREMENTS ON A
MONTH-TO-MONTH BASIS
* ZYVERSA THERAPEUTICS INC - WILL NEED ADDITIONAL FINANCING
TO
SUPPORT ITS CONTINUING OPERATIONS
* ZYVERSA THERAPEUTICS INC - TO SEEK TO FUND ITS OPERATIONS
THROUGH PUBLIC OR PRIVATE EQUITY OR DEBT FINANCINGS OR OTHER
SOURCES
Source text for Eikon: ID:nGNX7yNnCM
Further company coverage: ZVSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing